Esperion Therapeutics, Inc. (ESPR) Upgraded by Jefferies Group LLC to Buy
Esperion Therapeutics, Inc. (NASDAQ:ESPR) was upgraded by equities researchers at Jefferies Group LLC from a “hold” rating to a “buy” rating in a research note issued on Tuesday, The Fly reports.
A number of other analysts have also issued reports on ESPR. Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 1st. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Deutsche Bank AG initiated coverage on Esperion Therapeutics in a report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price objective on the stock. Finally, BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, June 25th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Esperion Therapeutics currently has an average rating of “Buy” and an average target price of $39.16.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 15.41% during trading on Tuesday, reaching $52.13. 4,147,332 shares of the company’s stock were exchanged. The firm’s market capitalization is $1.18 billion. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $57.38. The company’s 50-day moving average price is $44.47 and its 200 day moving average price is $33.65.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by $0.30. During the same quarter in the prior year, the firm earned ($0.62) EPS. Analysts predict that Esperion Therapeutics will post ($6.69) EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in ESPR. Quantbot Technologies LP bought a new position in Esperion Therapeutics during the first quarter worth approximately $158,000. C WorldWide Group Holding A S bought a new position in Esperion Therapeutics during the first quarter worth approximately $162,000. Princeton Alpha Management LP bought a new position in Esperion Therapeutics during the first quarter worth approximately $205,000. Bank of Montreal Can increased its position in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the period. Finally, Aperio Group LLC bought a new position in Esperion Therapeutics during the second quarter worth approximately $249,000. Institutional investors own 85.20% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.